Loading...
Reach Banner
Keywords
Last name
Institution

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Valerie Waters and Felix Ratjen.

 
Connection Strength
 
 
 
17.718
 
  1. Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev. 2020 06 10; 6:CD010004.
    View in: PubMed
    Score: 0.973
  2. Waters V, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev. 2017 10 05; 10:CD009528.
    View in: PubMed
    Score: 0.808
  3. Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2017 06 19; 6:CD006961.
    View in: PubMed
    Score: 0.792
  4. Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev. 2016 12 19; 12:CD010004.
    View in: PubMed
    Score: 0.765
  5. Waters V, Stanojevic S, Ratjen F. Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis. Expert Rev Respir Med. 2016 Nov; 10(11):1221-1228.
    View in: PubMed
    Score: 0.756
  6. Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2015 Nov 02; (11):CD006961.
    View in: PubMed
    Score: 0.707
  7. Waters V, Ratjen F. Pulmonary Exacerbations in Children with Cystic Fibrosis. Ann Am Thorac Soc. 2015 Nov; 12 Suppl 2:S200-6.
    View in: PubMed
    Score: 0.707
  8. Waters V, Stanojevic S, Klingel M, Chiang J, Sonneveld N, Kukkar R, Tullis E, Ratjen F. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2015 Nov; 14(6):770-6.
    View in: PubMed
    Score: 0.696
  9. Waters V, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev. 2015 Mar 05; (3):CD009528.
    View in: PubMed
    Score: 0.676
  10. Waters VJ, Stanojevic S, Sonneveld N, Klingel M, Grasemann H, Yau YC, Tullis E, Wilcox P, Freitag A, Chilvers M, Ratjen FA. Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. J Cyst Fibros. 2015 Nov; 14(6):755-62.
    View in: PubMed
    Score: 0.673
  11. Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev. 2014 Dec 03; (12):CD010004.
    View in: PubMed
    Score: 0.664
  12. Waters VJ, Ratjen FA. Is there a role for antimicrobial stewardship in cystic fibrosis? Ann Am Thorac Soc. 2014 Sep; 11(7):1116-9.
    View in: PubMed
    Score: 0.652
  13. Waters V, Ratjen F. Inhaled liposomal amikacin. Expert Rev Respir Med. 2014 Aug; 8(4):401-9.
    View in: PubMed
    Score: 0.641
  14. Waters V, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros. 2013 Sep; 12(5):482-6.
    View in: PubMed
    Score: 0.582
  15. Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev. 2012 Dec 12; 12:CD010004.
    View in: PubMed
    Score: 0.579
  16. Waters V, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev. 2012 Nov 14; 11:CD009528.
    View in: PubMed
    Score: 0.576
  17. Waters V, Stanojevic S, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J. 2012 Jul; 40(1):61-6.
    View in: PubMed
    Score: 0.539
  18. Waters V, Atenafu EG, Salazar JG, Lu A, Yau Y, Matukas L, Tullis E, Ratjen F. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J Cyst Fibros. 2012 Jan; 11(1):8-13.
    View in: PubMed
    Score: 0.528
  19. Waters V, Yau Y, Prasad S, Lu A, Atenafu E, Crandall I, Tom S, Tullis E, Ratjen F. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med. 2011 Mar 01; 183(5):635-40.
    View in: PubMed
    Score: 0.497
  20. Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2008 Jul 16; (3):CD006961.
    View in: PubMed
    Score: 0.427
  21. Waters V, Ratjen F. Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues. Expert Rev Anti Infect Ther. 2006 Oct; 4(5):807-19.
    View in: PubMed
    Score: 0.377
  22. Perrem L, Stanojevic S, Shaw M, Jensen R, McDonald N, Isaac SM, Davis M, Clem C, Guido J, Jara S, France L, Solomon M, Grasemann H, Waters V, Sweezey N, Sanders DB, Davis SD, Ratjen F. Lung Clearance Index to Track Acute Respiratory Events in School-age Children with Cystic Fibrosis. Am J Respir Crit Care Med. 2020 Oct 08.
    View in: PubMed
    Score: 0.249
  23. Somayaji R, Yau YCW, Tullis E, LiPuma JJ, Ratjen F, Waters V. Clinical Outcomes Associated with Burkholderia cepacia Complex Infection in Patients with Cystic Fibrosis. Ann Am Thorac Soc. 2020 Jul 17.
    View in: PubMed
    Score: 0.245
  24. Smith S, Waters V, Jahnke N, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev. 2020 06 10; 6:CD009528.
    View in: PubMed
    Score: 0.243
  25. Smith S, Ratjen F, Remmington T, Waters V. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2020 05 15; 5:CD006961.
    View in: PubMed
    Score: 0.242
  26. Klingel M, Stanojevic S, Tullis E, Ratjen F, Waters V. Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis. Ann Am Thorac Soc. 2019 07; 16(7):861-867.
    View in: PubMed
    Score: 0.228
  27. Middleton MA, Layeghifard M, Klingel M, Stanojevic S, Yau YCW, Zlosnik JEA, Coriati A, Ratjen FA, Tullis ED, Stephenson A, Wilcox P, Freitag A, Chilvers M, McKinney M, Lavoie A, Wang PW, Guttman DS, Waters VJ. Epidemiology of Clonal Pseudomonas aeruginosa Infection in a Canadian Cystic Fibrosis Population. Ann Am Thorac Soc. 2018 07; 15(7):827-836.
    View in: PubMed
    Score: 0.213
  28. Blanchard AC, Rooney AM, Yau Y, Zhang Y, Stapleton PJ, Horton E, Klingel M, Stanojevic S, Ratjen F, Coburn B, Waters V. Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment. J Cyst Fibros. 2018 11; 17(6):723-728.
    View in: PubMed
    Score: 0.208
  29. Somayaji R, Stanojevic S, Tullis DE, Stephenson AL, Ratjen F, Waters V. Clinical Outcomes Associated with Achromobacter Species Infection in Patients with Cystic Fibrosis. Ann Am Thorac Soc. 2017 Sep; 14(9):1412-1418.
    View in: PubMed
    Score: 0.201
  30. Waters V, Yau Y, Beaudoin T, Wettlaufer J, Tom SK, McDonald N, Rizvi L, Klingel M, Ratjen F, Tullis E. Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection. J Cyst Fibros. 2017 Jul; 16(4):492-495.
    View in: PubMed
    Score: 0.194
  31. Blanchard AC, Horton E, Stanojevic S, Taylor L, Waters V, Ratjen F. Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. J Cyst Fibros. 2017 May; 16(3):395-400.
    View in: PubMed
    Score: 0.193
  32. Stanojevic S, McDonald A, Waters V, MacDonald S, Horton E, Tullis E, Ratjen F. Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis. Thorax. 2017 04; 72(4):327-332.
    View in: PubMed
    Score: 0.187
  33. Wettlaufer J, Klingel M, Yau Y, Stanojevic S, Tullis E, Ratjen F, Waters V. Longitudinal study of Stenotrophomonas maltophilia antibody levels and outcomes in cystic fibrosis patients. J Cyst Fibros. 2017 01; 16(1):58-63.
    View in: PubMed
    Score: 0.185
  34. Ratjen F, Waters V, Klingel M, McDonald N, Dell S, Leahy TR, Yau Y, Grasemann H. Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J. 2016 Mar; 47(3):829-36.
    View in: PubMed
    Score: 0.177
  35. Yau YC, Ratjen F, Tullis E, Wilcox P, Freitag A, Chilvers M, Grasemann H, Zlosnik J, Speert D, Corey M, Stanojevic S, Matukas L, Leahy TR, Shih S, Waters V. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. J Cyst Fibros. 2015 Mar; 14(2):262-6.
    View in: PubMed
    Score: 0.165
  36. Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA. Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi. Ann Am Thorac Soc. 2014 Oct; 11(8):1298-306.
    View in: PubMed
    Score: 0.164
  37. Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc. 2014 Sep; 11(7):1120-9.
    View in: PubMed
    Score: 0.163
  38. Stanojevic S, Waters V, Mathew JL, Taylor L, Ratjen F. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis. J Cyst Fibros. 2014 Mar; 13(2):172-8.
    View in: PubMed
    Score: 0.153
  39. Stanojevic S, Ratjen F, Stephens D, Lu A, Yau Y, Tullis E, Waters V. Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. J Cyst Fibros. 2013 Dec; 12(6):575-83.
    View in: PubMed
    Score: 0.150
  40. Warren TA, Yau Y, Ratjen F, Tullis E, Waters V. Serum galactomannan in cystic fibrosis patients colonized with Aspergillus species. Med Mycol. 2012 Aug; 50(6):658-60.
    View in: PubMed
    Score: 0.138
  41. Leahy TR, Yau YC, Atenafu E, Corey M, Ratjen F, Waters V. Epidemiology of borderline oxacillin-resistant Staphylococcus aureus in pediatric cystic fibrosis. Pediatr Pulmonol. 2011 May; 46(5):489-96.
    View in: PubMed
    Score: 0.128
  42. Al-Saleh S, Dell SD, Grasemann H, Yau YC, Waters V, Martin S, Ratjen F. Sputum induction in routine clinical care of children with cystic fibrosis. J Pediatr. 2010 Dec; 157(6):1006-1011.e1.
    View in: PubMed
    Score: 0.122
  43. Lam W, Tjon J, Seto W, Dekker A, Wong C, Atenafu E, Bitnun A, Waters V, Yau Y, Solomon M, Ratjen F. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. J Antimicrob Chemother. 2007 Jun; 59(6):1135-40.
    View in: PubMed
    Score: 0.098
  44. Zemanick E, Burgel PR, Taccetti G, Holmes A, Ratjen F, Byrnes CA, Waters VJ, Bell SC, VanDevanter DR, Stuart Elborn J, Flume PA. Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. J Cyst Fibros. 2020 May; 19(3):370-375.
    View in: PubMed
    Score: 0.058
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.